

February 07, 2022

**BSE Limited**

P. J. Towers,  
Dalal Street,  
Mumbai- 400 001

**National Stock Exchange of India Limited**

Exchange Plaza, Plot No. C/1,  
G Block Bandra-Kurla Complex,  
Bandra (E) Mumbai- 400 051

**Scrip Code-540025**

**Trading Symbol-ADVENZYMES**

Dear Sir,

**Sub: Newspaper publication of Extract of Un-audited Consolidated Financial Results for the quarter and nine months ended December 31, 2021.**

**Ref: ISIN: INE837H01020**

Pursuant to the provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed copy of the newspaper publication of 'Extract of Un-audited Consolidated Financial Results for the quarter and nine months ended December 31, 2021' published in The Free Press Journal and Navshakti on February 06, 2021.


Thanking you,  
Yours faithfully,

**For Advanced Enzyme Technologies Limited**

**Sanjay Basantani**

**Company Secretary and Head – Legal**

Encl.: As above



## Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, LIC Service Road,  
Louiswadi, Thane - 400604, Maharashtra, India. Tel No : 91-22-41703220 Fax No: +91-22-25835159  
Website: [www.advancedenzymes.com](http://www.advancedenzymes.com), Email Id : [sanjay@advancedenzymes.com](mailto:sanjay@advancedenzymes.com)

### EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2021

(₹ in million except the Earnings per share)

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	Dec 31, 2021	Sep 30, 2021	Dec 31, 2020	Dec 31, 2021	Dec 31, 2020	Mar 31, 2021
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	Audited (Revised) (Refer note iii)
Total income from operations	1,335.58	1,270.77	1,377.38	3,976.49	3,686.25	5,018.41
Net Profit / (Loss) for the period (before tax, exceptional and/ or extraordinary items)	411.23	412.44	609.07	1,371.10	1,626.00	2,101.31
Net Profit / (Loss) for the period before tax (after exceptional and/ or extraordinary items)	411.23	412.44	609.07	1,371.10	1,626.00	2,101.31
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	285.55	302.70	443.03	985.44	1,176.67	1,512.86
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	280.70	281.42	413.44	1,031.89	1,066.89	1,413.56
Equity Share Capital	223.58	223.56	223.45	223.58	223.45	223.46
Reserves excluding Revaluation Reserve as per the last audited Balance Sheet						9,485.92
Earnings Per Share of ₹ 2 each (not annualised) (for continuing and discontinued operations)						
Basic	2.46	2.66	3.86	8.51	10.25	13.07
Diluted	2.45	2.65	3.85	8.50	10.24	13.04

Notes:

- (i) The above is an extract of the detailed format of consolidated unaudited financial results of Advanced Enzyme Technologies Limited (the "Company" or the "Holding Company") and the financial results of the subsidiary companies, Advanced Bio-Agro Tech Limited (India), Advanced Enzytech Solutions Limited (India), JC Biotech Private Limited (India), Scitech Specialities Private Limited (India) (w.e.f. 11 January 2021), Advanced Enzymes USA, Inc. (U.S.A.), Cal India Foods International (U.S.A.), Advanced Supplementary Technologies Corporation (U.S.A.), Enzyme Innovation, Inc. (U.S.A.), Dynamic Enzymes, Inc. (U.S.A.), Advanced Enzymes (Malaysia) Sdn. Bhd. (Malaysia), Advanced Enzymes Europe B.V. (Netherlands) and Evovx Technologies GmbH (Germany). The Holding Company and its subsidiary companies constitute the "Group".
- (ii) The above is an extract of the detailed format of consolidated unaudited financial results for the quarter and nine months ended 31 December 2021 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of quarterly results (standalone and consolidated) for the quarter and nine months ended 31 December 2021 are available on the Stock Exchange's website: [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) and on Company's website: [www.advancedenzymes.com](http://www.advancedenzymes.com).
- (iii) On 11 January 2021, the Group completed the acquisition of 51% of the paid up equity share capital in Scitech Specialities Private Limited ("SSPL") for a total consideration of Rs 316.26 million. As of 31 March 2021, the Group has accounted for the acquisition on provisional basis and finalised the purchase price allocation for the acquisition in the quarter ended on 30 September 2021 and accordingly, revised the provisional amounts of goodwill of Rs. 13.54 million. The Group on finalising of purchase price allocation has recognised fair value of Net Assets acquired of Rs. 320.00 million resulting in Capital reserve of Rs. 3.74 million. Also, the figures for the year ended 31 March 2021, quarter ended 30 September 2021 and quarter ended 31 December 2021, which includes figures for SSPL from the period 11 Jan 2021 to 31 March 2021, 1 July 2021 to 30 September 2021 and 1 October 2021 to 31 December 2021 respectively, are not comparable with the previous corresponding periods.
- (iv) Effective 18 August 2021, the Company has acquired additional stake of 15% in its subsidiary JC Biotech Private Limited for consideration of Rs 211.25 million. Post this additional acquisition the Company holds 85% stake in the subsidiary. On account of acquisition of additional stake of 15% by the Company in JC Biotech Private Limited Non-controlling interest has been reduced by Rs. 123.67 million and adjusted Rs. 87.58 million in other equity.
- (v) The above financial results of the Company were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 5 February 2022.
- (vi) The key standalone financial information are as under:

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	Dec 31, 2021	Sep 30, 2021	Dec 31, 2020	Dec 31, 2021	Dec 31, 2020	Mar 31, 2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total income from operations	643.87	649.11	791.45	2,020.50	2,128.65	2,834.73
Profit before tax	117.74	172.45	264.20	541.04	763.60	984.28
Profit after tax	87.68	128.41	203.17	401.57	557.72	710.12

By Order of the Board  
M.M. Kabra  
Wholetime Director  
DIN : 00148294

Place : Thane  
Date : 05<sup>th</sup> February, 2022



मुंबई, रविवार, ६ फेब्रुवारी २०२२ | नवशक्ति ११



## Advanced Enzyme Technologies Limited

CIN No.: L24200MH1989PLC051018

Regd. Office and Corporate Office: Sun Magnetica, 5th Floor, LIC Service Road,  
Louiswadi, Thane - 400604, Maharashtra, India. Tel No : 91-22-41703220 Fax No: +91-22-25835159  
Website: www.advancedenzymes.com, Email Id : sanjay@advancedenzymes.com

### EXTRACT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2021

(₹ in million except the Earnings per share)

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	Dec 31, 2021	Sep 30, 2021	Dec 31, 2020	Dec 31, 2021	Dec 31, 2020	Mar 31, 2021
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	Audited (Revised) (Refer note III)
Total income from operations	1,335.58	1,270.77	1,377.38	3,976.49	3,686.25	5,018.41
Net Profit / (Loss) for the period (before tax, exceptional and/ or extraordinary items)	411.23	412.44	609.07	1,371.10	1,626.00	2,101.31
Net Profit / (Loss) for the period before tax (after exceptional and/ or extraordinary items)	411.23	412.44	609.07	1,371.10	1,626.00	2,101.31
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	285.55	302.70	443.03	985.44	1,176.67	1,512.86
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	280.70	281.42	413.44	1,031.89	1,066.89	1,413.56
Equity Share Capital	223.58	223.56	223.45	223.58	223.45	223.46
Reserves excluding Revaluation Reserve as per the last audited Balance Sheet						9,485.92
Earnings Per Share of ₹ 2 each (not annualised) (for continuing and discontinued operations)						
Basic	2.46	2.66	3.86	8.51	10.25	13.07
Diluted	2.45	2.65	3.85	8.50	10.24	13.04

Notes:

- (i) The above is an extract of the detailed format of consolidated unaudited financial results of Advanced Enzyme Technologies Limited (the "Company" or the "Holding Company") and the financial results of the subsidiary companies, Advanced Bio-Agro Tech Limited (India), Advanced Enzytech Solutions Limited (India), JC Biotech Private Limited (India), Scitech Specialities Private Limited (India) (w.e.f. 11 January 2021), Advanced Enzymes USA, Inc. (U.S.A.), Cal India Foods International (U.S.A.), Advanced Supplementary Technologies Corporation (U.S.A.), Enzyme Innovation, Inc. (U.S.A.), Dynamic Enzymes, Inc. (U.S.A.), Advanced Enzymes (Malaysia) Sdn. Bhd. (Malaysia), Advanced Enzymes Europe B.V. (Netherlands) and Evox Technologies GmbH (Germany). The Holding Company and its subsidiary companies constitute the "Group".
- (ii) The above is an extract of the detailed format of consolidated unaudited financial results for the quarter and nine months ended 31 December 2021 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The full format of quarterly results (standalone and consolidated) for the quarter and nine months ended 31 December 2021 are available on the Stock Exchange's website: www.bseindia.com and www.nseindia.com and on Company's website: www.advancedenzymes.com.
- (iii) On 11 January 2021, the Group completed the acquisition of 51% of the paid up equity share capital in SciTech Specialities Private Limited ('SSPL') for a total consideration of Rs 316.26 million. As of 31 March 2021, the Group has accounted for the acquisition on provisional basis and finalised the purchase price allocation for the acquisition in the quarter ended on 30 September 2021 and accordingly, revised the provisional amounts of goodwill of Rs. 13.54 million. The Group on finalising of purchase price allocation has recognised fair value of Net Assets acquired of Rs. 320.00 million resulting in Capital reserve of Rs. 3.74 million. Also, the figures for the year ended 31 March 2021, quarter ended 30 September 2021 and quarter ended 31 December 2021, which includes figures for SSPL from the period 11 Jan 2021 to 31 March 2021, 1 July 2021 to 30 September 2021 and 1 October 2021 to 31 December 2021 respectively, are not comparable with the previous corresponding periods.
- (iv) Effective 18 August 2021, the Company has acquired additional stake of 15% in its subsidiary JC Biotech Private Limited for consideration of Rs 211.25 million. Post this additional acquisition the Company holds 85% stake in the subsidiary. On account of acquisition of additional stake of 15% by the Company in JC Biotech Private Limited Non-controlling interest has been reduced by Rs. 123.67 million and adjusted Rs. 87.58 million in other equity.
- (v) The above financial results of the Company were reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on 5 February 2022.
- (vi) The key standalone financial information are as under:

Particulars	Quarter Ended			Nine Months Ended		Year Ended
	Dec 31, 2021	Sep 30, 2021	Dec 31, 2020	Dec 31, 2021	Dec 31, 2020	Mar 31, 2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total income from operations	643.87	649.11	791.45	2,020.50	2,128.65	2,834.73
Profit before tax	117.74	172.45	264.20	541.04	763.60	984.28
Profit after tax	87.68	128.41	203.17	401.57	557.72	710.12

By Order of the Board

M.M. Kabra

Wholetime Director

DIN : 00148294

Place : Thane  
Date : 05<sup>th</sup> February, 2022